References
- KonecnyGEPaulettiGUntchMAssociation between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancerBreast Cancer Res Treat2010 doi: 10.1007/s10549-010-0744-z.
- BartlettJMSMunroACameronDAType 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trialJ Clin Oncol2008265027503518768436
- KawachiKSasakiTMurakamiAThe topoisomerase II alpha gene status in primary breast cancer is a predictive marker of the response to anthracycline-based neoadjuvant chemotherapyPathol Res Practice2010 doi: 10.1016/j.prp.2009.10.009.
- RodyAKarnTGatjeRGene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor responseBreast200716869317010609
- OrlandoLDel CurtoBGandiniSTopoisomerase IIα gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine nonresponsive Her2/neu-positive breast cancerBreast20081750651118456496
- ArpinoGCioccaDRWeissHPredictive value of apoptosis, proliferation, HER-2, and topoisomerase IIα for anthracycline chemotherapy in locally advanced breast cancerBreast Cancer Res Treat200592697515980993
- GennariASormaniMPronzatoPHER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trialsJ Natl Cancer Inst20081001142018159072
- BartlettJMSMunroAFDunnJAPredictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)Lancet2010 doi: 10.1016/s1470-2045(10)70006-1
- LiedtkeCMazouniCHessKRResponse to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancerJ Clin Onc200825812751281
- TherassePArbuckSGEisenhauerEANew guidelines to evaluate the response to treatment in solid tumorsJ Natl Cancer Inst20009220521610655437
- SPSS Version 170ChicagoSPSS, Inc2009
- Di LeoAIsolaJPietteFA meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. San Antonio Breast Cancer Symposium2008705 [abstract]
- HannemanJKristelPvan TinterenHMolecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapyBritish J Cancer20069513341341
- RodyAKarnTRuckhaberleEGene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancerBreast Cancer Res Treat200911345746618340528
- OakmanCMorettiEGalardiFThe role of topoisomerase IIα and HER-2 in predicting sensitivity to anthracyclines in breast cancer patientsCancer Treat Rev20093566266719758759
- PritchardKLMessersmithHElavathilLHER-2 and topoisomerase II as predictors of response to chemotherapyJ Clin Oncol20082673674418258981
- DevitaVTYoungRCCanellosGPCombination versus single agent chemotherapy: a review of the basis for selection of drug treatment for cancerCancer19753598110162854
- CareyLADeesECSawyerLThe triple negative paradox: Primary Tumor Chemosensitivity of Breast Cancer SubtypesClin Cancer Res2007132329233417438091
- JarvinenTATannerMRantanenVAmplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancerAm J Pathol200015683984710702400
- TenariNLattanzioRNatoliCChanges in topoisomerase IIα expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survivalClin Cancer Res20061251501150616533774
- EjlertsenBMaj-BrittJNielsenKVHER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patientsJ Clin Oncol20102898499020038724